The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer

IMPORTANCE: Gemcitabine-nab-paclitaxel (GEMNAB) and fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) both improve survival of patients with advanced pancreatic cancer when compared with single-agent gemcitabine in clinical trials. OBJECTIVE: To describe changes in the survival of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Raphael, Michael J., Raskin, William, Habbous, Steven, Tai, Xiaochen, Beca, Jaclyn, Dai, Wei F., Arias, Jessica, Forbes, Leta, Gavura, Scott, Biagi, James J., Earle, Craig C., Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593760/
https://www.ncbi.nlm.nih.gov/pubmed/34779846
http://dx.doi.org/10.1001/jamanetworkopen.2021.33388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593760/
https://www.ncbi.nlm.nih.gov/pubmed/34779846
http://dx.doi.org/10.1001/jamanetworkopen.2021.33388

Ejemplares similares